Innovative endocrinology of cancer:
Gespeichert in:
| Format: | Buch |
|---|---|
| Sprache: | English |
| Veröffentlicht: |
New York, NY
Springer [u.a.]
2008
|
| Schriftenreihe: | Advances in experimental medicine and biology
630 |
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis Inhaltsverzeichnis Inhaltsverzeichnis |
| Beschreibung: | XIX, 242 S. Ill., graph. Darst. |
| ISBN: | 9780387788173 0387788174 |
Internformat
MARC
| LEADER | 00000nam a2200000 cb4500 | ||
|---|---|---|---|
| 001 | BV035335467 | ||
| 003 | DE-604 | ||
| 005 | 20090508 | ||
| 007 | t | ||
| 008 | 090226s2008 ad|| |||| 00||| eng d | ||
| 010 | |a 2008006861 | ||
| 015 | |a 08N110765 |2 dnb | ||
| 016 | 7 | |a 987638904 |2 DE-101 | |
| 020 | |a 9780387788173 |c Gb. : ca. EUR 131.02 (freier Pr.), ca. sfr 213.50 (freier Pr.) |9 978-0-387-78817-3 | ||
| 020 | |a 0387788174 |c Gb. : ca. EUR 131.02 (freier Pr.), ca. sfr 213.50 (freier Pr.) |9 0-387-78817-4 | ||
| 035 | |a (OCoLC)192042330 | ||
| 035 | |a (DE-599)DNB987638904 | ||
| 040 | |a DE-604 |b ger |e rakddb | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-12 |a DE-355 | ||
| 050 | 0 | |a RC268.2 | |
| 082 | 0 | |a 616.99/4071 |2 22 | |
| 084 | |a XH 5300 |0 (DE-625)152911:12905 |2 rvk | ||
| 084 | |a XH 6100 |0 (DE-625)152923:13129 |2 rvk | ||
| 084 | |a 610 |2 sdnb | ||
| 245 | 1 | 0 | |a Innovative endocrinology of cancer |c ed. by Lev M. Berstein ... |
| 264 | 1 | |a New York, NY |b Springer [u.a.] |c 2008 | |
| 300 | |a XIX, 242 S. |b Ill., graph. Darst. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 1 | |a Advances in experimental medicine and biology |v 630 | |
| 650 | 0 | |a Cancer / Endocrine aspects | |
| 650 | 4 | |a Breast Neoplasms |x drug therapy | |
| 650 | 4 | |a Breast Neoplasms |x physiopathology | |
| 650 | 4 | |a Cancer |x Endocrine aspects | |
| 650 | 4 | |a Estrogen Receptor Modulators |x pharmacology | |
| 650 | 4 | |a Receptors, Estrogen |x physiology | |
| 650 | 4 | |a Receptors, Progesterone |x physiology | |
| 650 | 0 | 7 | |a Krebs |g Medizin |0 (DE-588)4073781-0 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Endokrinologie |0 (DE-588)4014663-7 |2 gnd |9 rswk-swf |
| 655 | 7 | |0 (DE-588)4143413-4 |a Aufsatzsammlung |2 gnd-content | |
| 689 | 0 | 0 | |a Krebs |g Medizin |0 (DE-588)4073781-0 |D s |
| 689 | 0 | 1 | |a Endokrinologie |0 (DE-588)4014663-7 |D s |
| 689 | 0 | |C b |5 DE-604 | |
| 700 | 1 | |a Berstein, Lev M. |e Sonstige |4 oth | |
| 830 | 0 | |a Advances in experimental medicine and biology |v 630 |w (DE-604)BV000003102 |9 630 | |
| 856 | 4 | |u http://www.loc.gov/catdir/toc/fy0804/2008006861.html |z kostenfrei |3 Inhaltsverzeichnis | |
| 856 | 4 | |m DE-601 |q pdf/application |u http://www.gbv.de/dms/bowker/toc/9780387788173.pdf |3 Inhaltsverzeichnis | |
| 856 | 4 | 2 | |m Digitalisierung UB Regensburg |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=017139842&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 940 | 1 | |n oe | |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-017139842 | ||
Datensatz im Suchindex
| _version_ | 1804138649407717376 |
|---|---|
| adam_text | CONTENTS
1.
MECHANISMS OF HORMONE CARCINOGENESIS:
EVOLUTION OF VIEWS, ROLE OF MITOCHONDRIA.
.................1
Jin-Qiang Chen, Terry R. Brown and James D. Yager
Abstract
................................................................................„..„„........„...............................1
Introduction..
........................................................................................................................1
A Novel Paradigm: Estrogen/Estrogen Receptor-Mediated
Mitochondria! Pathway
...............................................................................................2
Potential Role of E^R-Mediated Mitocbondrial Pathway in Estrogen
Carcinogenesis
».■.........»......·■■...»...■■»■«..—..»■..»·..■«■■.»■■.»■■■■..»..·■«...........»..■»..■»..■» 6
Deregulation of Mitochondrial Bioenergetics in Cancer Cells and Involvement
of Estrogens and ERs
................................................................................................10
Concluding Remarks, Evolutionary View and Future Directions
.................................11
2.
ADAPTATION TO ESTRADIOL DEPRIVATION CAUSES
UP-REGULATION OF GROWTH FACTOR PATHWAYS
AND HYPERSENSITIVITY TO ESTRADIOL IN BREAST
CANCERCELLS
______________________________________._____19
Richard J.
Santen,
Robert X. Song, Shigera
Masamura,
Wei Yue, Ping Fan,
Tetsuya Sogon, Shin-ichi Hayashi,
Kei
Nakachi and Hidtek Eguchi
Abstract
__._____.___________________________________________.__________19
Introduction........................................................................................................................
20
Phenomenon of Hypersensitivity: Mechanisms and Pathways
__________________20
Significance of Our Findings to Development of Further Therapies
_____________31
Synthesis of Our Current Thinking
_______________________________________31
3.
ROLE OF ENDOCRINE-GENOTOXIC SWITCHINGS
IN CANCER AND OTHER HUMAN DISEASES:
BASIC TRIAD
_______________________________________________35
Lev M. Berstein
Abstract................
__..............................................................___.....................................35
Introduction.»».........·..»..»..»..«......»·.»..«.·....».«·.·»..»....*..·......··.—
»».»....«..«·»«««.«..« 35
General Principle: Types of Effects
___________________________.-----------------36
Phenomenon of Switching of Estrogen Effects (PSEE)
------------------------------------36
Janus (Dual) Function of Glucose
____..-------------.—-------.—.------------»---------40
Adipogenotoiicosis
_____________________.----------------.-----------»----------.-----43
Basic Triad: Interactions and Implications
.................................................................... 46
xiii
ών
Contents
4.
BREAST DEVELOPMENT, HORMONES AND CANCER
-----------------52
Jose
Russo
and
Irma H.
Russo
Abstract....····.»...
.........................·...........···.......··.··.......·.··..........··...·..........··..·.··-·..............52
Introduction
--------------------------------------------------------------------------------------52
Defining the Cell of Origin of Breast Cancer
..................................................................52
Breast Architecture and Cancer
___________________................................................54
5.
EPIDEMIOLOGY OF HORMONE-ASSOCIATED CANCERS
AS A REFLECTION OF AGE
..............................................................57
Svetlana
V. Ukraintseva,
Konstantin
G. Aŕbeev
and Anatoli I. Yashin
Abstract..........................................................................................
.....................................57
Introduction
.■.■.···.■.■■■■■.·■»·.·■·.·■*■■.■··■······■.·■■.·■■■■····«··■·■■■■■■■■■.·.·.··■■■■■■■*.···.■·*.■....■···.·.·*....·...··· 57
Data Sources and Basic Definitions
.....__.............................___..................................... 59
Typical Age Patterns of Cancer Incidence and Mortality Rates
-------------------------59
Patterns and Trends of Incidence Rates for Hormone Associated Cancers
------------61
Conclusions
·.·.····.··„···.···.·.·············....·.··.·····...··„·.·.....······„«···»······„········...·...«»..».„··««„.««.„ 69
6.
OBESITY AND DIABETES EPIDEMICS:
CANCER REPERCUSSIONS
...............................................................72
Anette
Hjartåker,
Hilde Langseth
and
Elisabete
Weiderpass
Abstract...........
...................................................................................................................72
Introduction..».....·...........··...«............................................................................·.........·.....
73
Current Research on the Associations between Obesity and Diabetes
and the Risk of Cancer
.............____............................____.................................... 76
Cancer of the Digestive Organs
...................................................................................... 76
Respiratory Organs
...............·....................................·»·,.................................................. 81
Skin Melanoma
___..................___________________________________________81
Breast Cancer
____.______.______________________.______________________82
Female Genital Organs
________________________.________________________83
Male Genital Organs
_____________________.___________________.______.___85
Urinary Organs
..............................................................................__..............................86
Thyroid Cancer
_____________„_______„_________________________________87
Lymphoid and Haematopoietic Cancers....
___................___.___................__............. 87
Summary of Findings
.................................................. „...„ . 88
Concluding Remarks and Recommendations for Further Research
_____________88
7.
PROGESTERONE RECEPTOR ACTION: TRANSLATING
STUDIES IN BREAST CANCER MODELS TO CLINICAL
INSIGHTS
___________________________________________________94
Carol A.
Lange,
Carol A. Sartorius,
Hany
Abdel-Hafiz,
Monique
A. Spillman,
Kathryn B. Horwitz and
Britta
M. Jacobsen
Abstr«ct.....„.™..„..„......„„„..............„......„......„....„„„„..„.„„.„......„..„..„„.„„,„„„„„„„„94
..„,.H..„..„..........„..........„..H..H„„„„..„HH...........,..H(...,.HaM,(.H..H
мш
„., „ 94
Contents
xv
Classical Actions of PRs
________________________________________________95
Direct PR Phosphorylation in Breast Cancer Models
______________.......................96
PR Ser294 Pbosphorylation in Breast Cancer Models
...................................................97
Extranuclear Actions of PR.............
.........................„.......................................................98
Integration of Rapid Signaling and Nuclear SR Actions
______________________100
PR Action and Breast Cancer Cell Growth, Apoptosis and Aggressiveness
in Vitro
________________________________________________________101
Expression Profiling in Vitro
__......................................................................................102
ProgestJns and Antiprogestins in Breast Tumor Models
________............................102
Progesterone Regulation of BRCA1
...............................................................................103
General Steroid Receptors and Breast Cancer
.............................................................104
Progesterone Receptors and Tamoxifeu Responsiveness
.............................................104
Clinical Significance of PR-Avs. PR-B: Two Subsets of ER+, PR+ Tumors?
______104
Concluding Remarks
.......................................................................................................105
8.
AROMATASE EXPRESSION IN WOMEN S CANCERS
......................112
Serdar
E.
Bulim
and Evan
R.
Simpson
Abstract
___.______........______________________.________________________112
Introduction
......................................................................................................................112
Pathological Expression of Aromatase in Women s Cancers
.......................................116
Conclusion
........................................................................................................................127
9.
PROTEOMICS OF CANCER OF HORMONE-DEPENDENT
TISSUES
................................................................................................133
Darren R. Tyson and David K. Ornstein
Abstract
.............................................................................................................................133
Introduction and Overview
...».. ..»....».»...»■»··.·.»■··«■..»» ··«»· .».«··».■.«·· «·..·.··«.». 133
Biomarkers
versus Biology..........................................
....................................................135
Cancer Proteomics: Sample Sources and Methodological Approaches
...................... 135
Recent Innovations and Technological Advances..........................................................
142
Tbe Future of Clinical Proteomics
................................................................................142
10.
ENDOGENOUS HORMONE
LEVELSAND
RISK OF BREAST,
ENDOMETRIAL AND OVARIAN CANCERS:
PROSPECTIVE STUDIES
..................................................................148
A. Heather Eliassen and Susan E. Hankinson
Abstract................................................................................
............................................. 148
Introduction·»»·«·»··»«»·«.«»·.»·»».»»»»»»» »»»..· ·» »»» »·· » »»»·» .»»·»»
148
Méthodologie
Considerations.......................................
__.».,«»........»..»..»..»..„,.»...... 149
Breast Cancer
__...........__.„...........„...».»..»..»..„» .....«...»..__.....__»»..».........».....,.150
Endometrial Cancer.....................................................
.................................................... 156
Ovarian Cancer»..·..»..·».·»»»..».»··.»»·
...............».·»»».«. . ·.· ««..»»««·.»»» ».«.·..«. 157
Conclusions
.......................................................................................................................159
Summarv·»
· »· »··· · ·».·
..«•»••»»•»••»••»»»»m«»»»«·««··«» »··»»·»«·»»·«» . «· ·
ló !
Tfì
Contents
11. HORMONAL
HETEROGENEITY OF ENDOMETRIAL
CANCER
...............................................................................................166
Carsten Gründker,
Andreas
R.
Günthert
and
Günter Emons
Abstract...
..........................................................................................................................166
Introduction
.. ..»........................................................................................ 166
Etiology
.............................................■...·■...■·■....................................................................167
Estrogen-Associated Endometria) Cancer (Type I)
-------------------.--------------.—168
Non-Estrogen-Associated Endometrial Cancer (Type
Π)------------------------------
168
Uterine Carcinosarcomas (Malignant Mixed Mttllerian Tumors)
.............................. 170
Molecular Pathogenesis of Endometrial Cancer
-----------------------------------------170
Hormone Receptors and Aromatase
____________________________________176
Future Perspective
___________________..................................................................178
12.
CELL CYCLE MACHINERY: LINKS WITH GENESIS
AND TREATMENT OF BREAST CANCER
....................................189
Alison J. Butt, C. Elizabeth Caldon, Catriona M. McNeil, Alexander Swarbrick,
Elizabeth A. Musgrove and Robert L. Sutherland
Abstract
_______________________________________________________.....189
Introduction.....................................................................................................................
189
Cell Cycle Control Mechanisms and Their Regulation in Breast Cancer Cells.........
190
Cell Cycle Control Genes as Putative Breast Cancer Oncogenes/Tunior
Suppressor Genes
.....................................................................................................194
Relationship of Cell Cycle Deregulation to Patient Outcome and Response
to Endocrine Therapy.«
......................................................................................198
Conclusion
........................................................................................................................ 201
13.
SELECTIVE ESTROGEN MODULATORS AS AN
ANTICANCER
TOOL: MECHANISMS OF EFFICIENCY
AND RESISTANCE
..............................................................................206
Surojeet Sengupta and V. Craig Jordan
Abstract
_____________________________________.___._________________206
Introduction.............................................................
.............„......„......„..„......_..„.......... 206
Estrogen, Tamoxifen and Cancer
................................................................................... 208
Molecular Mechanism of SERM Action
____„___._____________________.____209
Evolution of SERM Resistant Breast Cancers
________________________.____211
Mechanism of SERM Resistance
_________.____________________________. 211
Therapeutic Options for SERM Resistant Breast Cancers
___________________213
Resistance to Long Term
Antihormone
Therapy
..„..„..„......„..„.._.„„„..„................„ 214
Estrogen Induced Apoptosis
_________„______„„„.___________._____.______214
Conclusion»
____„.„________________„_____._______„.._______________214
Contents
xvii
14.
PHARMACOGENOMICS OF ENDOCRINE THERAPY
IN BREAST CANCER
.........................................................................220
Richard Weinshilboum
Abstract.
............................................................................................................................220
Introduction
.........................................................................____._________________220
Tamoxifeo Pbarmacogenomics
.......................................................................................221
Aromatase Inhibitor Pharmacogenomics
_________________________________228
Conclusions and Future Directions
................................................................................229
15.
PREVENTION OF BREAST CANCER USING SERMS
......................232
Trevor J. Powles
Abstract
_________________________________.______________........................232
Introduction.......................
...............................................................................................232
Tamoxifen Trials......
.........................................................................................................232
Raloxifene Trials
____________________________________________________234
Summary of SERM Breast Cancer Risk Reduction Trials
..........................................235
Conclusion
.......................................................................................................................235
GENERAL CONCLUSION
.............................................................................237
INDEX
................................................................................................................239
|
| any_adam_object | 1 |
| building | Verbundindex |
| bvnumber | BV035335467 |
| callnumber-first | R - Medicine |
| callnumber-label | RC268 |
| callnumber-raw | RC268.2 |
| callnumber-search | RC268.2 |
| callnumber-sort | RC 3268.2 |
| callnumber-subject | RC - Internal Medicine |
| classification_rvk | XH 5300 XH 6100 |
| ctrlnum | (OCoLC)192042330 (DE-599)DNB987638904 |
| dewey-full | 616.99/4071 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.99/4071 |
| dewey-search | 616.99/4071 |
| dewey-sort | 3616.99 44071 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02503nam a2200589 cb4500</leader><controlfield tag="001">BV035335467</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20090508 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">090226s2008 ad|| |||| 00||| eng d</controlfield><datafield tag="010" ind1=" " ind2=" "><subfield code="a">2008006861</subfield></datafield><datafield tag="015" ind1=" " ind2=" "><subfield code="a">08N110765</subfield><subfield code="2">dnb</subfield></datafield><datafield tag="016" ind1="7" ind2=" "><subfield code="a">987638904</subfield><subfield code="2">DE-101</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780387788173</subfield><subfield code="c">Gb. : ca. EUR 131.02 (freier Pr.), ca. sfr 213.50 (freier Pr.)</subfield><subfield code="9">978-0-387-78817-3</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0387788174</subfield><subfield code="c">Gb. : ca. EUR 131.02 (freier Pr.), ca. sfr 213.50 (freier Pr.)</subfield><subfield code="9">0-387-78817-4</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)192042330</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DNB987638904</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakddb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-12</subfield><subfield code="a">DE-355</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC268.2</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.99/4071</subfield><subfield code="2">22</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">XH 5300</subfield><subfield code="0">(DE-625)152911:12905</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">XH 6100</subfield><subfield code="0">(DE-625)152923:13129</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">610</subfield><subfield code="2">sdnb</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Innovative endocrinology of cancer</subfield><subfield code="c">ed. by Lev M. Berstein ...</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">New York, NY</subfield><subfield code="b">Springer [u.a.]</subfield><subfield code="c">2008</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XIX, 242 S.</subfield><subfield code="b">Ill., graph. Darst.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Advances in experimental medicine and biology</subfield><subfield code="v">630</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Cancer / Endocrine aspects</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Breast Neoplasms</subfield><subfield code="x">drug therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Breast Neoplasms</subfield><subfield code="x">physiopathology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cancer</subfield><subfield code="x">Endocrine aspects</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Estrogen Receptor Modulators</subfield><subfield code="x">pharmacology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Receptors, Estrogen</subfield><subfield code="x">physiology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Receptors, Progesterone</subfield><subfield code="x">physiology</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Krebs</subfield><subfield code="g">Medizin</subfield><subfield code="0">(DE-588)4073781-0</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Endokrinologie</subfield><subfield code="0">(DE-588)4014663-7</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)4143413-4</subfield><subfield code="a">Aufsatzsammlung</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Krebs</subfield><subfield code="g">Medizin</subfield><subfield code="0">(DE-588)4073781-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Endokrinologie</subfield><subfield code="0">(DE-588)4014663-7</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="C">b</subfield><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Berstein, Lev M.</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">Advances in experimental medicine and biology</subfield><subfield code="v">630</subfield><subfield code="w">(DE-604)BV000003102</subfield><subfield code="9">630</subfield></datafield><datafield tag="856" ind1="4" ind2=" "><subfield code="u">http://www.loc.gov/catdir/toc/fy0804/2008006861.html</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="856" ind1="4" ind2=" "><subfield code="m">DE-601</subfield><subfield code="q">pdf/application</subfield><subfield code="u">http://www.gbv.de/dms/bowker/toc/9780387788173.pdf</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">Digitalisierung UB Regensburg</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=017139842&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="940" ind1="1" ind2=" "><subfield code="n">oe</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-017139842</subfield></datafield></record></collection> |
| genre | (DE-588)4143413-4 Aufsatzsammlung gnd-content |
| genre_facet | Aufsatzsammlung |
| id | DE-604.BV035335467 |
| illustrated | Illustrated |
| indexdate | 2024-07-09T21:31:33Z |
| institution | BVB |
| isbn | 9780387788173 0387788174 |
| language | English |
| lccn | 2008006861 |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-017139842 |
| oclc_num | 192042330 |
| open_access_boolean | 1 |
| owner | DE-12 DE-355 DE-BY-UBR |
| owner_facet | DE-12 DE-355 DE-BY-UBR |
| physical | XIX, 242 S. Ill., graph. Darst. |
| publishDate | 2008 |
| publishDateSearch | 2008 |
| publishDateSort | 2008 |
| publisher | Springer [u.a.] |
| record_format | marc |
| series | Advances in experimental medicine and biology |
| series2 | Advances in experimental medicine and biology |
| spelling | Innovative endocrinology of cancer ed. by Lev M. Berstein ... New York, NY Springer [u.a.] 2008 XIX, 242 S. Ill., graph. Darst. txt rdacontent n rdamedia nc rdacarrier Advances in experimental medicine and biology 630 Cancer / Endocrine aspects Breast Neoplasms drug therapy Breast Neoplasms physiopathology Cancer Endocrine aspects Estrogen Receptor Modulators pharmacology Receptors, Estrogen physiology Receptors, Progesterone physiology Krebs Medizin (DE-588)4073781-0 gnd rswk-swf Endokrinologie (DE-588)4014663-7 gnd rswk-swf (DE-588)4143413-4 Aufsatzsammlung gnd-content Krebs Medizin (DE-588)4073781-0 s Endokrinologie (DE-588)4014663-7 s b DE-604 Berstein, Lev M. Sonstige oth Advances in experimental medicine and biology 630 (DE-604)BV000003102 630 http://www.loc.gov/catdir/toc/fy0804/2008006861.html kostenfrei Inhaltsverzeichnis DE-601 pdf/application http://www.gbv.de/dms/bowker/toc/9780387788173.pdf Inhaltsverzeichnis Digitalisierung UB Regensburg application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=017139842&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Innovative endocrinology of cancer Advances in experimental medicine and biology Cancer / Endocrine aspects Breast Neoplasms drug therapy Breast Neoplasms physiopathology Cancer Endocrine aspects Estrogen Receptor Modulators pharmacology Receptors, Estrogen physiology Receptors, Progesterone physiology Krebs Medizin (DE-588)4073781-0 gnd Endokrinologie (DE-588)4014663-7 gnd |
| subject_GND | (DE-588)4073781-0 (DE-588)4014663-7 (DE-588)4143413-4 |
| title | Innovative endocrinology of cancer |
| title_auth | Innovative endocrinology of cancer |
| title_exact_search | Innovative endocrinology of cancer |
| title_full | Innovative endocrinology of cancer ed. by Lev M. Berstein ... |
| title_fullStr | Innovative endocrinology of cancer ed. by Lev M. Berstein ... |
| title_full_unstemmed | Innovative endocrinology of cancer ed. by Lev M. Berstein ... |
| title_short | Innovative endocrinology of cancer |
| title_sort | innovative endocrinology of cancer |
| topic | Cancer / Endocrine aspects Breast Neoplasms drug therapy Breast Neoplasms physiopathology Cancer Endocrine aspects Estrogen Receptor Modulators pharmacology Receptors, Estrogen physiology Receptors, Progesterone physiology Krebs Medizin (DE-588)4073781-0 gnd Endokrinologie (DE-588)4014663-7 gnd |
| topic_facet | Cancer / Endocrine aspects Breast Neoplasms drug therapy Breast Neoplasms physiopathology Cancer Endocrine aspects Estrogen Receptor Modulators pharmacology Receptors, Estrogen physiology Receptors, Progesterone physiology Krebs Medizin Endokrinologie Aufsatzsammlung |
| url | http://www.loc.gov/catdir/toc/fy0804/2008006861.html http://www.gbv.de/dms/bowker/toc/9780387788173.pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=017139842&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| volume_link | (DE-604)BV000003102 |
| work_keys_str_mv | AT bersteinlevm innovativeendocrinologyofcancer |
Es ist kein Print-Exemplar vorhanden.
Inhaltsverzeichnis
Inhaltsverzeichnis